Company profile · Sponsor
Dr.
Dr. Falk Pharma GmbH
- Pipeline
- 11
- Drugs
- 0
- Patents
- 0
Quick answer
Dr. (EF3ECEC) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (11)
Search pipeline →-
NUC01, Placebo to NUC01
Dr.
primary sclerosing cholangitis (PSC)
1 trial -
NUT01
Dr.
Primary Sclerosing Cholangitis (PSC)
1 trial -
Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets
Dr.
eosinophilic esophagitis
1 trial -
BUL02, Placebo orodispersible tablets, BUL03
Dr.
Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
1 trial -
Budenofalk 4 mg Zäpfchen, placebo to test
Dr.
Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
1 trial -
NAT01, NAT03, Placebo film coated tablets, NAT02
Dr.
Idiopathic or Diabetic Gastroparesis
1 trial -
Placebo matching with ZED1227 capsules of Dr. Falk Pharma GmbH, CEC02, CEC03
Dr.
Celiac Disease
1 trial -
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
Dr.
Idiopathic or diabetic gastroparesis
1 trial -
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
Dr.
Primary Sclerosing Cholangitis (PSC)
1 trial -
Evaluation of the Effect of Food, Itraconazole, and Rifampicin on the Single-Dose Pharmacokinetics of Naronapride.
Dr.
No medical condition.
1 trial -
Evaluation of the Effect of Itraconazole, Quinidine and Rifampicin on the Single-Dose Pharmacokinetics of ZED1227
Dr.
No medical condition.
1 trial
Frequently asked questions
What is Dr.?
Dr. (EF3ECEC) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Dr. sponsor?
We track 11 ClinicalTrials.gov-linked programs for Dr., including NUC01, Placebo to NUC01 and 10 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Dr. company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.